Cited by 147Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsLipid metabolism and disorders

The DOI matches its Crossref record; 124 of the 129 references it cites were found in a registry or an index.

Fibrates for primary prevention of cardiovascular disease events

Open access

Jakob, Tobias, Nordmann, Alain J, Schandelmaier, Stefan, Ferreira-González, Ignacio, Briel, Matthias·2016·Cochrane Database of Systematic Reviews

DOI 10.1002/14651858.cd009753.pub2PMC PMC6464497

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Fibrates are effective for modifying atherogenic dyslipidaemia, and particularly for lowering serum triglycerides. However, evidence that fibrates reduce mortality and morbidity associated with cardiovascular disease (CVD), or overall mortality and morbidity, in the primary prevention of CVD is lacking. OBJECTIVES: This Cochrane Review and meta-analysis aimed to evaluate the clinical benefits and harms of fibrates versus placebo or usual care or fibrates plus other lipid-modifying drugs versus other lipid-modifying drugs alone for the primary prevention of cardiovascular disease (CVD) morbidity and mortality. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), and Web of Science (all from inception to 19 May 2016). We searched four clinical trial registers (last searched on 3 August 2016) with the help of an experienced professional librarian. We searched the databases to identify randomised controlled trials (RCTs) evaluating the clinical effects of fibrate therapy in the primary prevention of CVD events. We did not impose any language restrictions. SELECTION CRITERIA: We aimed to include all RCTs comparing the effects of fibrate monotherapy versus placebo or usual care, or fibrates plus other lipid-modifying drugs versus other lipid-modifying drugs alone. Included studies had a follow-up of at least six months for the primary prevention of CVD events. We excluded trials with clofibrate, because it was withdrawn from the market in 2002. DATA COLLECTION AND ANALYSIS: statistic to measure inconsistency of treatment effects across studies. Using the GRADE approach, we assessed the quality of the evidence and used the GRADE profiler software (GRADEpro GDT) to import data from Review Manager 5 to create 'Summary of findings' tables. MAIN RESULTS: = 74%; very low-quality of evidence). Data on quality of life were not available from any trial. Trials that evaluated fibrates in the background of statins (2 studies) showed no benefits in preventing cardiovascular events. AUTHORS' CONCLUSIONS: Moderate-quality evidence suggests that fibrates lower the risk for cardiovascular and coronary events in primary prevention, but the absolute treatment effects in the primary prevention setting are modest (absolute risk reductions < 1%). There is low-quality evidence that fibrates have no effect on overall or non-CVD mortality. Very low-quality evidence suggests that fibrates are not associated with increased risk for adverse effects.

Integrity signals

Registry

Crossref · 10.1002/14651858.cd009753.pub2

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902

Show all 129 references

Research works printed but not linked: 8

Domagala TB Kotula-Horowitz K Januszek R Janczura M Zagajewski J Musial J The effect of fenofibrate therapy on plasma homocysteine levels and endothelial dysfunction in the subjects with metabolic syndrome Journal of Diabetes 2013 46 7
Kawano, 2013, Effects of combination lipid therapy on lipid profiles in patients with impaired glucose tolerance, Journal of Diabetes, 5, 112
Arthur, 1971, Trial of clofibrate in the treatment of ischemic heart disease, British Medical Journal, 4, 767
Scott, 2010, A 6-month randomised study of the combination of fenofibrate and simvastatin in patients with mixed dyslipidaemia at risk of cardiovascular disease not adequately controlled by simvastatin 40 mg alone, European Heart Journal, 31, 390
Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, New England Journal of Medicine, 362, 1563, 10.1056/NEJMoa1001282 · DOI · Paper page
Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, New England Journal of Medicine, 341, 410, 10.1056/NEJM199908053410604 · DOI · Paper page
Department of Economic and Social Affairs, 2003, Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments. Eighth Issue - Pharmaceuticals

Sorted by citations

Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 345
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 282
SIRT1 promotes lipid metabolism and mitochondrial biogenesis in adipocytes and coordinates adipogenesis by targeting key enzymatic pathways
Majeed, Y., Halabi, N. M., Madani, A. Y., Engelke, R., Bhagwat, A. M., Abdesselem, H., Agha, M. V., Vakayil, M., Courjaret, R. J., Goswami, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87759-x · Cited by 220
Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
PPARs: Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease. Part I: PPAR-α
Han, L., Shen, W., Bittner, S., Kraemer, F. B., & Azhar, S. (2017) · Future Cardiology · doi:10.2217/fca-2016-0059 · Cited by 194
Fibrates for secondary prevention of cardiovascular disease and stroke
Wang, D., Liu, B., Tao, W., Hao, Z., & Liu, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009580.pub2 · Cited by 142
Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia
Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141
Oleuropein: A natural antioxidant molecule in the treatment of metabolic syndrome
Ahamad, J., Toufeeq, I., Khan, M. A., Ameen, M. S. M., Anwer, E. T., Uthirapathy, S., Mir, S. R., & Ahmad, J. (2019) · Phytotherapy Research · doi:10.1002/ptr.6511 · Cited by 140
The pharmacological management of metabolic syndrome
Larsen, J. R., Dima, L., Correll, C. U., & Manu, P. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1429910 · Cited by 121
Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
Zodda, D., Giammona, R., & Schifilliti, S. (2018) · Pharmacy · doi:10.3390/pharmacy6010010 · Cited by 116
Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study
Oscarsson, J., Önnerhag, K., Risérus, U., Sundén, M., Johansson, L., Jansson, P., Moris, L., Nilsson, P. M., Eriksson, J. W., & Lind, L. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.08.003 · Cited by 114
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 84
Disentangling Genetic Risks for Metabolic Syndrome
van Walree, E. S., Jansen, I. E., Bell, N. Y., Savage, J. E., de Leeuw, C., Nieuwdorp, M., van der Sluis, S., & Posthuma, D. (2022) · Diabetes · doi:10.2337/db22-0478 · Cited by 76
Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis
Generoso, G., Janovsky, C. C. P. S., & Bittencourt, M. S. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000468 · Cited by 72
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
Kastelein, J. J. P., Hsieh, A., Dicklin, M. R., Ditmarsch, M., & Davidson, M. H. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01184-1 · Cited by 69
Nonstatin Therapies for Management of Dyslipidemia: A Review
Sando, K. R., & Knight, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.001 · Cited by 69
Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases
Khuchua, Z. A., Glukhov, A. I., Strauss, A. W., & Javadov, S. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113464 · Cited by 62
Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics
Swerdlow, D. I., Rider, D. A., Yavari, A., Lindholm, M., Campion, G., & Nissen, S. E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab100 · Cited by 58
Treatment of Dyslipidemia in Common Liver Diseases
Speliotes, E. K., Balakrishnan, M., Friedman, L. S., & Corey, K. E. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.023 · Cited by 56
Apolipoprotein C-II: the re-emergence of a forgotten factor
Wolska, A. T., Reimund, M., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000680 · Cited by 58
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?
Sharma, A., Mah, M., Ritchie, R. H., & Blasio, M. J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108008 · Cited by 52
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 55
Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications
Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 48
The Effect of Fibrates on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis of Randomised Studies
Hadjivasilis, A., Kouis, P., Kousios, A., & Panayiotou, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030768 · Cited by 46
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Moon, J. H., Kim, K., & Choi, S. H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.402 · Cited by 53
Cardiac maturation
Sakamoto, T., & Kelly, D. P. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.12.008 · Cited by 50
Targeting PPARα for the Treatment and Understanding of Cardiovascular Diseases
Li, S., Yang, B., Du, Y., Lin, Y., Liu, J., Huang, S., Zhang, A.-H., Jia, Z., & Zhang, Y. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495969 · Cited by 48
Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point
Rogosnitzky, M., Berkowitz, E., & Jadad, A. R. (2020) · JMIR Public Health and Surveillance · doi:10.2196/19199 · Cited by 43
Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults
Yang, Z., Amar, M. J., Sampson, M. L., Courville, A. B., Sorokin, A. V., Gordon, S. M., Aponte, A. M., Stagliano, M. S., Playford, M. P., Fu, Y., et al. (2020) · Nutrients · doi:10.3390/nu12030749 · Cited by 43
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis
Yamashita, S., Rizzo, M., Su, T., & Masuda, D. (2023) · Metabolites · doi:10.3390/metabo13050626 · Cited by 43
The Evolving Story of Triglycerides and Coronary Heart Disease Risk
Návar, A. M. (2019) · JAMA · doi:10.1001/jama.2018.20044 · Cited by 39
Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks
Shemesh, E., & Zafrir, B. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188856 · Cited by 38
A low-fat spread with added plant sterols and fish omega-3 fatty acids lowers serum triglyceride and LDL-cholesterol concentrations in individuals with modest hypercholesterolaemia and hypertriglyceridaemia
Blom, W. A. M., Koppenol, W. P., Hiemstra, H., Stojaković, T., Scharnagl, H., & Trautwein, E. A. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1706-1 · Cited by 38
PPAR α Targeting GDF11 Inhibits Vascular Endothelial Cell Senescence in an Atherosclerosis Model
Dou, F., Wu, B., Chen, J., Liu, T., Yu, Z., & Chen, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/2045259 · Cited by 32
Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence
Gupta, K. K., Ali, S., & Sanghera, R. S. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0123-0 · Cited by 35
COSMIC project: consensus on the objectives of the metabolic syndrome in clinic
Pedro‐Botet, J., Ascaso, J. F., Barrios, V., de la Sierra, A., Escalada, J., Millán, J., Mostaza, J. M., Pérez‐Martínez, P., Pintó, X., Salas‐Salvadó, J., et al. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s165740 · Cited by 31
A new phenotypic classification system for dyslipidemias based on the standard lipid panel
Sampson, M. L., Ballout, R. A., Soffer, D. E., Wolska, A. T., Wilson, S. R., Meeusen, J. W., Donato, L. J., Fatica, E. M., Otvos, J. D., Brinton, E. A., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01585-8 · Cited by 34
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
Drexel, H., Tamargo, J. L., Kaski, J. C., Lewis, B. S., Saely, C. H., Fraunberger, P., Dobrev, D., Komiyama, M., PLATTNER, T., Agewall, S., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad044 · Cited by 32
Coronary Artery Disease
Cagle, S., & Cooperstein, N. (2018) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2017.10.001 · Cited by 28
Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care
Hartz, J. C., de Ferranti, S. D., & Gidding, S. S. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00079 · Cited by 29
Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies
Vyletelová, V., Nováková, M., & Pašková, Ľ. (2022) · Pharmaceuticals · doi:10.3390/ph15101278 · Cited by 30
Palmitoleoylethanolamide Is an Efficient Anti-Obesity Endogenous Compound: Comparison with Oleylethanolamide in Diet-Induced Obesity
Tovar, R., Gavito, A., Vargas, A., Soverchia, L., Hernández‐Folgado, L., Jagerovic, N., Baixerás, E., Ciccocioppo, R., de Fonseca, F. R., & Decara, J. M. (2021) · Nutrients · doi:10.3390/nu13082589 · Cited by 27
Associations of metabolic disorders with hypertension and cardiovascular disease: recent findings and therapeutic perspectives
Tanaka, A., & Node, K. (2024) · Hypertension Research · doi:10.1038/s41440-024-01737-0 · Cited by 27
Blood-Derived Lipid and Metabolite Biomarkers in Cardiovascular Research from Clinical Studies: A Recent Update
Kale, D., Fatangare, A., Phapale, P. B., & Sickmann, A. (2023) · Cells · doi:10.3390/cells12242796 · Cited by 24
Dyslipidemia in Renal Transplant Recipients
Chmielnicka, K., Heleniak, Z., & Dębska-Ślizień, A. M. (2022) · Transplantology · doi:10.3390/transplantology3020020 · Cited by 24
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 26
The Polymorphisms of the Peroxisome-Proliferator Activated Receptors’ Alfa Gene Modify the Aerobic Training Induced Changes of Cholesterol and Glucose
Maciejewska, A., Buryta, M., Czarny, W., Król, P., Spieszny, M., Šťastný, P., Petr, M., Safranow, K., & Sawczuk, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071043 · Cited by 24
An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α
Sharma, S., Sharma, D., Dhobi, M., Wang, D., & Tewari, D. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04755-7 · Cited by 23
Auraptene, a citrus peel-derived natural product, prevents myocardial infarction-induced heart failure by activating PPARα in rats
Sunagawa, Y., Kawaguchi, S., Miyazaki, Y., Katanasaka, Y., Funamoto, M., Shimizu, K., Shimizu, S., Hamabe‐Horiike, T., Kawase, Y., Komiyama, M., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154457 · Cited by 22
The use of blood biomarkers in precision medicine for the primary prevention of atherosclerotic cardiovascular disease: a review
Sweeney, T. E., Quispe, R., Das, T. M., Juraschek, S. P., Martin, S. S., & Michos, E. D. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1930531 · Cited by 24
Adverse drug reactions of non-statin antihyperlipidaemic drugs in China from 1989 to 2019: a national database analysis
Tsui, L., Chen, L., Ye, P., Xu, S., Wu, S., Chen, S. C.-I., & Xie, W. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068915 · Cited by 20
Present and Future of Dyslipidaemia Treatment—A Review
Merćep, I., Vujević, A., Strikić, D., Radman, I. B., Pećin, I., & Reiner, Ž. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185839 · Cited by 23
Triglyceride Lowering Drugs
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Effect of n-3 polyunsaturated fatty acids on ischemic heart disease and cardiometabolic risk factors: a two-sample Mendelian randomization study
Xu, B., Xu, Z., Xu, D., & Tan, X. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02342-6 · Cited by 17
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care
Dugré, N., Lindblad, A. J., Perry, D., Allan, G. M., Braschi, É., Falk, J., Froentjes, L. S., Garrison, S., Kirkwood, J. E. M., Korownyk, C. S., et al. (2023) · Canadian Family Physician · doi:10.46747/cfp.6910701 · Cited by 20
A brief overview of currently used atherosclerosis treatment approaches targeting lipid metabolism alterations.
Poznyak, A. V., Zhang, D., Orekhova, V. A., Grechko, A. V., Wetzker, R., & Orekhov, A. N. (2020) · PubMed Central · Cited by 17
Large-scale metabolomic profiling and incident non-alcoholic fatty liver disease
Gagnon, É., Manikpurage, H. D., Mitchell, P. L., Girard, A. S., Gobeil, É., Bourgault, J., Bégin, F., Marette, A., Thériault, S., & Arsenault, B. J. (2023) · iScience · doi:10.1016/j.isci.2023.107127 · Cited by 15
Joint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
Wang, W., Li, R. P., Song, Z., Huang, N., Huang, T., Hua, X., & Tang, Y.-D. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0195 · Cited by 16
The Association of Triglyceride to High-Density Lipoprotein Cholesterol Ratio with High-Risk Coronary Plaque Characteristics Determined by CT Angiography and Its Risk of Coronary Heart Disease
Koide, Y., Miyoshi, T., Nishihara, T., Nakashima, M., Ichikawa, K., Miki, T., Osawa, K., & Ito, H. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9100329 · Cited by 16
The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
Takeda, Y., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., & Sakurai, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1094100 · Cited by 15
Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials
Blais, J. E., Tong, G. K. Y., Pathadka, S., Mok, M. T. C., Wong, I. C. K., & Chan, E. W. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246480 · Cited by 15
Gemfibrozil Induces Anemia, Leukopenia and Reduces Hematopoietic Stem Cells via PPAR-α in Mice
Estrela, G. R., Arruda, A. C., Torquato, H. F. V., Freitas‐Lima, L. C., Perilhão, M. S., Wasinski, F., Budu, A., Fock, R. A., Paredes‐Gamero, E. J., & Araújo, R. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145050 · Cited by 14
Current Management and Future Perspectives in the Treatment of Lp(a) with a Focus on the Prevention of Cardiovascular Diseases
Farina, J., Pereyra, M., Mahmoud, A., Chao, C., Barry, T., Demeter, S. H., Ayoub, C., & Arsanjani, R. (2023) · Pharmaceuticals · doi:10.3390/ph16070919 · Cited by 13
Fenofibrate therapy to lower serum triglyceride concentrations in persons with spinal cord injury: A preliminary analysis of its safety profile
Fountaine, M. F. L., Cirnigliaro, C. M., Hobson, J. C., Lombard, A. T., Specht, A. F., Dyson‐Hudson, T. A., & Bauman, W. A. (2019) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.2019.1581694 · Cited by 13
Unraveling mitochondrial crosstalk: a new frontier in heart failure pathogenesis
Chang, H., He, P., Liu, W., Wu, H., & Wang, Z. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1641023 · Cited by 13
Long-Term Effect of Zhenzhu Tiaozhi Capsule (FTZ) on Hyperlipidemia: 2-Year Results from a Retrospective Study Using Electronic Medical Records
Huang, X., Zhan, H., Yang, J. M., Peng, L., Piao, S., Wang, L., Lan, T., Rong, X., & Guo, J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6264414 · Cited by 10
Lactate: A Theranostic Biomarker for Metabolic Psychiatry?
Caddye, E., Pineau, J., Reyniers, J., Ronen, I., & Colasanti, A. (2023) · Antioxidants · doi:10.3390/antiox12091656 · Cited by 11
Lipid-Lowering Therapy and Cardiovascular Prevention in Elderly
Baratta, F., Moscucci, F., Lospinuso, I., Cocomello, N., Colantoni, A., Costanzo, A. D., Tramontano, D., D’Erasmo, L., Pastori, D., Ettorre, E., et al. (2025) · Drugs · doi:10.1007/s40265-025-02182-0 · Cited by 11
Molecular regulators of lipid metabolism in the intestine – Underestimated therapeutic targets for obesity?
Dávalos-Salas, M., Mariadason, J. M., Watt, M. J., & Montgomery, M. K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114091 · Cited by 11
No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19
Rogosnitzky, M., Berkowitz, E., & Jadad, A. R. (2020) · JMIRx Med · doi:10.2196/19583 · Cited by 10
Effect of Pemafibrate on Serum Creatinine in Patients with Chronic Kidney Disease
Imai, E., & Imai, A. (2022) · JMA Journal · doi:10.31662/jmaj.2021-0212 · Cited by 10
Very low HDL levels: clinical assessment and management
Bonilha, I., Luchiari, B., Nadruz, W., & Sposito, A. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000585 · Cited by 12
Coagulopathy in Malnourished Mice Is Sexually Dimorphic and Regulated by Nutrient‐Sensing Nuclear Receptors
Preidis, G. A., Soni, K. G., Suh, J. H., Halder, T., Kim, K. H., Choi, J. M., Li, F., Devaraj, S., Conner, M. E., Coarfa, C., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1622 · Cited by 9
Centrality analysis in a drug network and its application to drug repositioning
Keng, Y. Y., Kwa, K. H., & Ratnavelu, K. (2020) · Applied Mathematics and Computation · doi:10.1016/j.amc.2020.125870 · Cited by 8
Triglyceride/high density lipoprotein cholesterol index and future cardiovascular events in diabetic patients without known cardiovascular disease
Nakashima, R., Ikeda, S., Shinohara, K., Matsumoto, S., Yoshida, D., Ono, Y., Nakashima, H., Miyamoto, R., Matsushima, S., Kishimoto, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-92933-6 · Cited by 11
Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom
Mistry, H., Enderby, J., Court, R. A., Al-Khudairy, L., Nduka, C. U., Meléndez‐Torres, G. J., Taylor‐Phillips, S., Clarke, A., & Uthman, O. A. (2022) · Health Technology Assessment · doi:10.3310/qovk6659 · Cited by 7
HDL-C: Helpful, harmful, hopeful, or guilty by association
McLean, P., Mathew, D., Chandrasekhar, S. A., Guynn, N., Razavi, A. C., Quyyumi, A. A., Mehta, A., & Sperling, L. S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.017 · Cited by 7
Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects
Duprez, D. A., Handelsman, Y., & Koren, M. J. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s261719 · Cited by 8
Association between venous thromboembolism events and fibrates: A comparative study
Dolladille, C., Humbert, X., Faucon, M., Tournilhac, C., Sassier, M., Fédrizzi, S., Milliez, P., Lelong‐Boulouard, V., Coquerel, A., Puddu, P. E., et al. (2018) · Therapies · doi:10.1016/j.therap.2018.10.001 · Cited by 7
A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury
Fountaine, M. F. L., Cirnigliaro, C. M., Hobson, J. C., Lombard, A. T., Specht, A. F., Dyson‐Hudson, T. A., Kirshblum, S., & Bauman, W. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-53753-7 · Cited by 7
Selective PPARα Modulator (SPPARMα) in the Era of the MASLD Pandemic: Current Insights and Future Prospects
Sugihara, T. (2025) · Yonago acta medica · doi:10.33160/yam.2025.05.002 · Cited by 8
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors as Adjunct Therapy to Statins: A New Frontier in Cardiovascular Risk Reduction
Lamia, T. H., Shah-Riar, P., Khanam, M., Khair, F., Sadat, A., Tania, M. K., Haque, S. M., Saaki, S. S., Ferdausi, A., Naurin, S. A., et al. (2024) · Cureus · doi:10.7759/cureus.71365 · Cited by 8
Emerging agents targeting triglycerides
Prakash, Y. S., Bhatt, D. L., & Malick, W. A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000979 · Cited by 7
Impact of Statin or Fibrate Therapy on Homocysteine Concentrations: A Systematic Review and Meta-analysis
Akbari, A., Islampanah, M., Arhaminiya, H., Fard, M. M. A., Jamialahmadi, T., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230413090416 · Cited by 6
Cardiovascular Disease
Sell, J. K., & Nunez, J. J. (2023) · doi:10.1093/med/9780197679098.003.0039 · Cited by 6
UK deal over inclisiran
Byrne, P., Cullinan, J., Mintzes, B. J., & Smith, S. M. (2020) · BMJ · doi:10.1136/bmj.m579 · Cited by 6
Therapeutics in Metabolic Diseases
Natesan, V. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_17 · Cited by 5
Anti-inflammatory Drug Combination Therapy for Atherosclerosis: Colchicine and Fenofibrate
Spartalis, Μ., Tzima, I. G., Anastasiou, A., Spartalis, E. D., Iliopoulos, D., & Siasos, G. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220407095216 · Cited by 5
Drugs linked to plasma homoarginine in chronic kidney disease patients—a cross-sectional analysis of the German Chronic Kidney Disease cohort
Maas, R., Mieth, M., Titze, S. I., Hübner, S., Fromm, M. F., Kielstein, J. T., Schmid, M. C., Köttgen, A., Kronenberg, F., Krane, V., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy342 · Cited by 5
Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review
Pryor, J. B., Weber, B. R., Weber, J. V., Lockridge, J. B., & Olyaei, A. J. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00646-4 · Cited by 5
Fibrinogen As a Cardiovascular Risk Marker
Gasparoto, A. L. V., Martinez, T. L. D. R., Saldanha, A. L. R., & Margeotto, A. P. P. (2021) · Journal of Internal Medicine and Cardiovascular Research · doi:10.55124/jimc.v1i1.85 · Cited by 5
Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration
Brea, Á., Millán, J., Ascaso, J. F., Blasco, M., Díaz, A., Hernández‐Mijares, A., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2018) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2018.06.002 · Cited by 5
Fibrates : Do They Still Have a Role in Therapy in 2025?
Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01379-8 · Cited by 4
Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocyte
Hattori, N., Yamada, A., Nakatsuji, S., Matsuda, T., Nishiyama, N., & Shimatsu, A. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-21-0239 · Cited by 5
Pathological mechanism of heart failure with preserved ejection fraction in rats based on iTRAQ technology
Xu, H., Gao, K., Liu, C., Li, T. X., Ding, Y., & Ma, J. (2023) · PeerJ · doi:10.7717/peerj.15280 · Cited by 4
Pharmacotherapeutics for dyslipidemia management
Hussein, M. T. E., Sharma, A., Parmar, K., & Shelat, K. (2023) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000059 · Cited by 4
Non-alcoholic fatty liver disease and risk of cardiovascular diseases: clinical association, pathophysiological mechanisms, and management
Yang, R., & Fan, J. (2023) · Cardiology Plus · doi:10.1097/cp9.0000000000000067 · Cited by 3

Authors: Jakob, T., Nordmann, A. J., Schandelmaier, S., Ferreira-González, I., & Briel, M.
Affiliations: University of Basel (CH)
Vall d'Hebron Hospital; Cardiology Department, Epidemiology Unit; Passeig Vall d'Hebron 119-129 Barcelona Barcelona Spain 08035
ORCID: Schandelmaier, Stefan
Briel, Matthias
Venue: Cochrane Database of Systematic Reviews
Publisher: Wiley
Published: 2016-11-16
Volume: 2017
Issue: 3
Pages: CD009753-CD009753
ISSN: 1361-6137 (ISSN-L)
1465-1858
DOI: 10.1002/14651858.cd009753.pub2
PMC: PMC6464497
OpenAlex: W1918267826
Cited by: 147
References: 129
Citations by year: 2026: 2 · 2025: 12 · 2024: 11 · 2023: 25 · 2022: 18 · 2021: 16 · 2020: 16 · 2019: 15 · 2018: 21 · 2017: 8 · 2016: 1
FWCI: 2.97
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cochrane Database of Systematic Reviews (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: British Heart Foundation
European Society of Cardiology
Medical Research Council
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords: fibrates, primary prevention, cardiovascular disease, cardiovascular events, coronary events, triglycerides, lipid-modifying drugs, statins, atherogenic dyslipidemia, mortality, adverse effects, quality of life
MeSH terms: Atorvastatin, Hypolipidemic Agents, Bezafibrate, Cardiovascular Diseases, Clofibric Acid, Humans, Middle Aged, Myocardial Infarction, Primary Prevention, Fenofibrate, Gemfibrozil, Simvastatin, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fibrates for primary prevention of cardiovascular disease events

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks